Zim Laboratories share price
NSE: ZIMLABBSE: 541400Pharmaceuticals & BiotechnologySmall Cap
Last close ₹126.22down ₹5.90 (4.47%)BSE ₹126.60
Share price at the NSE close on 23 Oct 2026. Previous close ₹132.12.
52-week range of traded prices to 23 Oct 2026
₹59.31Low, 30 Mar 2026₹159.81High, 12 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹677 Cr1,933rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 6 Aug 2026
- 183.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 19 May 2026
- 2.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 6 Aug 2026
- 1.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 6 Aug 2026
- 1.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 19 May 2026
- 0.42
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,16,71445.7% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 6 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹94 Crdown 10.54%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹4.02 CrQuarter to Mar 2026: ₹3.74 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −4.3%
Revenue by year
Peak revenue ₹399 Cr, year to Mar 2023
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 9 Nov | Dec 2024Filed 10 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 7 Aug | Sep 2025Filed 12 Nov | Dec 2025Filed 11 Feb | Mar 2026Filed 19 May | Jun 2026Filed 6 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 92 | 96 | 109 | 72 | 89 | 109 | 105 | 94 |
| Net profit | 2 | 4 | 5 | −2 | 0 | 4 | 4 | −4 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 2.6% | 4.2% | 4.5% | −2.6% | −0.5% | 4.0% | 3.6% | −4.3% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmacuetical Industry, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 98% of 1,960 trading days since Nov 2018.
LowestHighest
Its median28.0Industry median28.1
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 78% of 1,788 trading days since May 2019.
LowestHighest
Its median1.7Industry median2.9
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.26.8
At or below today's level on 98% of 1,788 trading days since May 2019.
LowestHighest
Its median10.3Industry median18.7
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −25.2% | −56.3% | +71.2% | 0.0% |
| 3 years | −5.9% | −39.9% | +56.5% | 0.0% |
| 5 years | +20.1% | −6.2% | +28.0% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count. Earnings growth over 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2021.
Mutual funds holding it
1 fund disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 1
| Fund | |||
|---|---|---|---|
 Tata India Pharma & Healthcare FundTata Mutual Fund | 6,31,193 | 0.58% | ₹8.71 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Zim Laboratories in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Shree Ganesh RemediesSGRL | 805 | 52.2 | 4.9 | 26.5 | −8.8% | −29.4% | 10.0% | 10.6% | 0.00% |
 Anuh PharmaANUHPHR | 768 | 17.4 | 2.2 | 11.7 | +9.7% | −4.3% | 13.0% | 15.2% | 1.96% |
 Kilitch Drugs (India)KILITCH | 707 | 23.5 | 2.5 | 21.5 | +14.0% | – | 12.5% | 8.9% | 0.00% |
 Valiant LaboratoriesVALIANTLAB | 698 | 43.6 | 2.2 | 22.1 | +89.6% | +12,324.8% | 5.9% | 7.0% | 0.00% |
 Amanta HealthcareAMANTA | 633 | 43.1 | 2.9 | 13.0 | – | – | 6.7% | 9.0% | 0.00% |
 WanburyWANBURY | 624 | 11.2 | 4.3 | 8.4 | +3.6% | +30.0% | 54.9% | 23.3% | 0.00% |
 Influx HealthtechINFLUX | 595 | 28.9 | 5.9 | – | – | – | 20.4% | – | 0.00% |
 TranschemTRANSCHEM | 513 | 76.2 | 6.1 | – | −100.0% | +47.5% | 8.3% | −4.9% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
8 Oct · Rating
Sep 2026
Aug 2026
Zim Laboratories share price by year
Each calendar year to 2025.Zim Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 72.15 | −32.9% | 120.82 | 67.85 |
| 2024 | 107.52 | −6.8% | 124.40 | 92.45 |
| 2023 | 115.35 | +18.7% | 149.00 | 68.90 |
| 2022BSE close | 97.20 | +146.6% | 123.18 | 38.15 |
| 2021BSE close | 39.42 | +31.2% | 60.58 | 23.67 |
| 2020BSE close | 30.03 | +27.7% | 36.52 | 15.35 |
| 2019BSE close | 23.52 | −51.6% | 55.40 | 18.60 |
| 2018BSE close | 48.57 | – | 156.67 | 42.00 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2018 is from its first session, 11 Jun 2018.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 130.80 | 130.80 | 121.41 | 126.22 | 125.54 | 1,16,714 | 45.7% |
| 22 Oct 2026 | 130.63 | 134.43 | 130.63 | 132.12 | 132.36 | 73,408 | 56.7% |
| 21 Oct 2026 | 138.20 | 143.00 | 125.63 | 132.29 | 132.16 | 2,17,138 | 46.2% |
| 19 Oct 2026 | 145.60 | 146.57 | 135.81 | 138.17 | 140.52 | 63,229 | 50.2% |
| 16 Oct 2026 | 140.19 | 148.00 | 138.50 | 144.76 | 144.42 | 1,75,033 | 33.4% |
| 15 Oct 2026 | 145.45 | 146.90 | 139.20 | 140.30 | 142.07 | 68,533 | 56.6% |
| 14 Oct 2026 | 146.80 | 148.99 | 142.50 | 145.43 | 146.57 | 1,06,571 | 42.4% |
| 13 Oct 2026 | 152.00 | 153.93 | 144.10 | 146.77 | 146.91 | 2,25,889 | 26.8% |
| 12 Oct 2026 | 155.10 | 159.81 | 152.00 | 152.63 | 154.98 | 4,91,098 | 32.6% |
| 9 Oct 2026 | 141.00 | 153.94 | 138.69 | 150.47 | 149.27 | 5,54,208 | 25.5% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 4 Aug 2025 | Price move | – | Between two trading sessions the price moved by a fifth or more. The company made an announcement in time for trading that day or the trading day before. Not adjusted for. |
| 22 Dec 2022 | Bonus | 0.3333 | Holders received 2 bonus shares for every 1 held. |
| 4 Oct 2018 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- Legal name
- Zim Laboratories Limited
- NSE symbol
- ZIMLAB
- BSE code
- 541400
- ISIN
- INE518E01015
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Jun 2018 on BSE, Nov 2022 on NSE
- Face value
- ₹10
- CIN
- L99999MH1984PLC032172
- Corporate identity number, the registrar of companies' code for it